Company & Sponsor Intelligence
Naurex, Inc, an affiliate of Allergan plc
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed1
Countries2
Therapeutic footprint
depression
Indexed studies
NCT03668600Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT03675776Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
depression · HungaryPHASE3
depression · HungaryPHASE3
NCT02932943A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
depression · United StatesPHASE3
depression · United StatesPHASE3
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →